{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:19:07Z","timestamp":1794406747236,"version":"4.9.0"},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.2169\/internalmedicine.5027-20","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T22:05:39Z","timestamp":1598047539000},"page":"131-136","source":"Crossref","is-referenced-by-count":5,"title":["Mycophenolate Mofetil-induced Diffuse Large B-cell Lymphoma in Which a Solitary Lung Nodule Remitted Spontaneously"],"prefix":"10.2169","volume":"60","author":[{"given":"Hiroshi","family":"Kobe","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hayata","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Ohara Healthcare Foundation, Kurashiki Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Rheumatology, Ohara Healthcare Foundation, Kurashiki Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Ohara Healthcare Foundation, Kurashiki Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127: 2375-2390, 2016.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"2","unstructured":"2. Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol 18: 1741-1743, 1991."},{"key":"3","unstructured":"3. Kubica MG, Sangle NA. Iatrogenic immunodeficiency-associated lymphoproliferative disorders in transplant and nontransplant settings. Indian J Pathol Microbiol 59: 6-15, 2016."},{"key":"4","unstructured":"4. Kim HJ, Ko YH, Kim JE, et al. Epstein-Barr virus-associated lymphoproliferative disorders: review and update on 2016 WHO Classification. J Pathol Transl Med 51: 352-385, 2017."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Waldman MA, Callen JP. Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate. J AM Acad Dermatol 51: 124-130, 2004.","DOI":"10.1016\/j.jaad.2004.03.020"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Dasqupta N, Gelber AC, Racke F, Fine DM. Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis. Lupus 14: 910-913, 2005.","DOI":"10.1191\/0961203303lu2179cr"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Vernino S, Salomao DR, Habermann TM, O'Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology 23: 639-641, 2005.","DOI":"10.1212\/01.wnl.0000173031.56429.04"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Finelli PF, Naik K, DiGiuseppe JA, Prasad A. Primary lymphoma of CNS, mycophenolate mofetil and lupus. Lupus 15: 886-888, 2006.","DOI":"10.1177\/0961203306071431"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. O'Neill BP, Vernino S, Dogan A, Giannini C. EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil. Neuro Oncol 9: 364-369, 2007.","DOI":"10.1215\/15228517-2007-004"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Dubal DB, Mueller S, Ruben BS, Enqstrom JW, Josephson SA. T-cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gravis. Muscle Nerve 39: 849-850, 2009.","DOI":"10.1002\/mus.21306"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Adams B, Lazarchick J, Medina AM, et al. Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. Am J Hematol 85: 627-629, 2010.","DOI":"10.1002\/ajh.21753"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tsang HH, Trendell-Smith NJ, Wu AK, Mok MY. Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus. Lupus 19: 330-333, 2010.","DOI":"10.1177\/0961203309347921"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Svobodova B, Hruskova Z, Rysava R, Tesar V. Brain diffuse large B-cell lymphoma in a systemic lupus erythematosus patient treated with immunosuppressive agents including mycophenolate mofetil. Lupus 20: 1452-1454, 2011.","DOI":"10.1177\/0961203311412413"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Balci MA, Pamuk GE, Unlu E, Usta U, Pamuk ON. Development of primary central nervous system lymphoma in a systemic lupus erythematosus patient after treatment with mycophenolate mofetil and review of the literature. Lupus 26: 1224-1227, 2017.","DOI":"10.1177\/0961203317691370"},{"key":"15","unstructured":"15. Inui Y, Matsuoka H, Yakushiji K, et al. Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. Leuk Lymphoma 56: 3045-3051, 2015."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Saito S, Kaneko Y, Yamaoka K, Tokuhira M, Takeuchi T. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatology (Oxford) 56: 940-946, 2017.","DOI":"10.1093\/rheumatology\/kex002"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Walling J. From methotrexate to pemetrexed and beyond. a review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 24: 37-77, 2006.","DOI":"10.1007\/s10637-005-4541-1"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47: 85-118, 2000.","DOI":"10.1016\/S0162-3109(00)00188-0"},{"key":"19","unstructured":"19. Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 91: 20-28, 2013."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Tokuhira M, Saito S, Okuyama A, et al. Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. Leuk Lymphoma 59: 1143-1152, 2018.","DOI":"10.1080\/10428194.2017.1369073"},{"key":"21","unstructured":"21. Kurita D, Miyoshi H, Ichikawa A, et al. Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis: clinicopathologic features and prognostic factors. Am J Surg Pathol 43: 869-884, 2019."},{"key":"22","unstructured":"22. Gion Y, Iwaki N, Takata K, et al. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: comparison of diffuse large B-cell lymphoma and classical hodgkin lymphoma types. Cancer Sci 108: 1271-1280, 2017."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/1\/60_5027-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T03:49:17Z","timestamp":1609559357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/1\/60_5027-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5027-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}